Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance

Supernus Pharmaceuticals (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported record financial results for the fourth quarter and full year 2017 and associated Company developments.

As quoted in the press release:

Fourth quarter 2017 product prescriptions for Trokendi XR^® and Oxtellar XR^®, as reported by IQVIA (formerly IMS), totaled 198,715, a 47.3% increase over the fourth quarter of 2016. Full year 2017 product prescriptions for Trokendi XR^® and Oxtellar XR^®, as reported by IQVIA, totaled 672,709, a 33.8% increase over full year 2016.

Click here to read the full press release.